CRISPR Therapeutics AG(CRSP)Earnings, Financials & Key RatiosCRISPR Therapeutics AG (CRSP) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on equity-based funding and persistent net losses, exemplified by a -84.3% net margin in 2026Q1, suggests that the current business model lacks the self-sustaining commercial scale required to justify its current valuation.
CRISPR Therapeutics AG (CRSP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
CRISPR Therapeutics AG (CRSP) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $1.28vs $1.19-7.5% | $1Mvs $6M-76.0% |
| Q1 2026 | Feb 12, 2026 | $1.37vs $1.15-19.1% | $864,000vs $5M-81.7% |
| Q4 2025 | Nov 10, 2025 | $1.17vs $1.26+7.1% | $889,000vs $9M-90.3% |
| Q3 2025 | Aug 4, 2025 | $1.29vs $1.47+12.2% | $892,000vs $9M-90.5% |
Recent stock market news and headlines for CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while maintaining a robust cash position. Vertex Pharmaceuticals offers a profitable portfolio anchored by cystic fibrosis treatments alongside expansion into gene therapy and pain management.
CRISPR Therapeutics AG (CRSP) closed at $54.92 in the latest trading session, marking a +1.74% move from the prior day.
Exploring some of the top bargains in a multi-trillion-dollar industry.
The opportunity is enormous, but uncertainty remains.
Key metrics vs top competitors for CRISPR Therapeutics AG (CRSP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $60.77 | $5.86B | -9.39 | -89.97% | -16569.77% | -30.18% | — | |
| $3.75 | $367.15M | -2.08 | 25.39% | -281.59% | -677.39% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $0.07 | $30.66M | -0.17 | -31.57% | -356.89% | — | — | |
| $3.99 | $720.66M | -2.96 | 55.28% | -4917.55% | -188.82% | — |
CRISPR Therapeutics AG (CRSP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRISPR Therapeutics AG (CRSP) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 4, 2026·SEC
Mar 16, 2026·SEC
Mar 11, 2026·SEC
Get notified when CRSP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CRISPR Therapeutics AG (CRSP) stock FAQ — growth, dividends, profitability & financials explained
CRISPR Therapeutics AG (CRSP) reported $4.1M in revenue for fiscal year 2025.
CRISPR Therapeutics AG (CRSP) saw revenue decline by 90.0% over the past year.
CRISPR Therapeutics AG (CRSP) reported a net loss of $568.5M for fiscal year 2025.
CRISPR Therapeutics AG (CRSP) has a return on equity (ROE) of -30.2%. Negative ROE indicates the company is unprofitable.
CRISPR Therapeutics AG (CRSP) had negative free cash flow of $401.2M in fiscal year 2025, likely due to heavy capital investments.
